相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 应用范围:
产品信息以Bioss网站为准
- 规格:
50ul/100ul/200ul
| 规格: | 50ul | 产品价格: | ¥1180.0 |
|---|---|---|---|
| 规格: | 100ul | 产品价格: | ¥1980.0 |
| 规格: | 200ul | 产品价格: | ¥2800.0 |
| 产品编号 | bs-2698R |
| 英文名称 | MCT4/SLC16A3 Rabbit pAb |
| 中文名称 | 单羧酸转运蛋4抗体 |
| 英文别名 | Monocarboxylate transporter 4; Slc16a3; Mct3; Mct4; MCT-4; Monocarboxylate transporter 3; solute carrier family 16 member 3; SLC16A3; MOT4_HUMAN. |
| 产品应用 | WB=1:500-2000 Not yet tested in other applications. |
| 交叉反应 | Mouse, Rat (Human, Cow, Horse) |
| 抗体来源 | Rabbit |
| 免疫原 | KLH conjugated synthetic peptide derived from human SLC16A3 |
| 亚型 | IgG |
| 性状 | Liquid |
| 纯化方法 | affinity purified by Protein A |
| 克隆类型 | Polyclonal |
| 理论分子量 | 52 kDa |
| 浓度 | 1mg/ml |
| 储存液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 亚细胞定位 | Cell membrane; Multi-pass membrane protein. |
| 组织特异性 | Highly expressed in skeletal muscle. |
| 相似性 | Belongs to the major facilitator superfamily. Monocarboxylate porter (TC 2.A.1.13) family. |
| 功能 | Proton-linked monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. |
| 保存条件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 背景资料 | Lactic acid and pyruvate transport across plasma membranes is catalyzed by members of the proton-linked monocarboxylate transporter (MCT) family, which has been designated solute carrier family-16. Each MCT appears to have slightly different substrate and inhibitor specificities and transport kinetics, which are related to the metabolic requirements of the tissues in which it is found. The MCTs, which include MCT1 (SLC16A1; MIM 600682) and MCT2 (SLC16A7; MIM 603654), are characterized by 12 predicted transmembrane domains (Price et al., 1998 [PubMed 9425115]).[supplied by OMIM, Mar 2008] |
| 应用 | 推荐稀释比例 |
| {WB} | {1:500-2000} |

Lane 1: Mouse Muscle tissue lysates
Lane 2: Rat Muscle tissue lysates
Primary: Anti-MCT4/SLC16A3 (bs-2698R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 52 kD
Observed band size: 50 kD
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验[IF={{ 8.8 }}] {Yunjia Zhang. et al. Macrophage MCT4 inhibition activates reparative genes and protects from atherosclerosis by histone H3 lysine 18 lactylation. CELL REP. 2024 May;43:} {WB} {Human}
[IF={{ 6.78 }}] {P.P.M. Scariot. et al. Monocarboxylate transporters (MCTs) in skeletal muscle and hypothalamus of less or more physically active mice exposed to aerobic training. LIFE SCI. 2022 Oct;307:120872} {WB} {Mouse}
[IF={{ 6.78 }}] {Pedro Paulo Menezes Scariot. et al. Living high - training low model applied to C57BL/6J mice: Effects on physiological parameters related to aerobic fitness and acid-base balance. LIFE SCI. 2023 Mar;317:121443} {WB} {Mouse}
[IF={{ 5.8 }}] {Xu Jianguo. et al. PDGF-BB accelerates TSCC via fibroblast lactates limiting miR-26a-5p and boosting mitophagy. CANCER CELL INT. 2024 Dec;24(1):1-18} {IHC} {Human}
[IF={{ 5.6 }}] {Juan B. Orsi. et al. Critical Velocity, Maximal Lactate Steady State, and Muscle MCT1 and MCT4 after Exhaustive Running in Mice. INT J MOL SCI. 2023 Jan;24(21):15753} {WB} {Mouse}
= NAL), appears to form upon oxidative cyclization of the nonfluorescent 2:1 lysine-HNE Michael adduct-Schiff base cross-link (Scheme 1). Polyclonal antibody (PAb) to the NAL-HNE fluorophore was raised in rabbit and found to be highly specific
. Retrieved 2010-11-29. ^ Nielsen BS, Jørgensen S, Fog JU, Søkilde R, Christensen IJ, Hansen U, Brünner N, Baker A, Møller S, Nielsen HJ (October 2010). "High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival
+oieSKeKcgxGinlRPl7uja5iYeDdc+K3eZhXhIOHOy+p9cxrGU9WCTkVcT5iRR/BsR+N0IDPSu3x0pXo0IRAQiAhGBiEBE4ABCwPnwbu0wGmW8ULj7NRb20DLRYqFW1Up6ODBube+wknwaZ5w/y92bXLbV5K3CJ+hhzKwdSHCmVrada2Qy0eyxvi0r7Lkl99ukcaOkRe60Sj82E8qgnmxNtzHGRRyZQtf1g41GIMau5W7ITlqbiDRR0CA3tPhIsEdmP5hZ
技术资料暂无技术资料 索取技术资料









